Dashtipour, K.; Lee, H.S.; Ellenbogen, A.; Kazerooni, R.; Gross, T.M.; Hollander, D.A.; Gallagher, C.J.
Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins 2024, 16, 442.
https://doi.org/10.3390/toxins16100442
AMA Style
Dashtipour K, Lee HS, Ellenbogen A, Kazerooni R, Gross TM, Hollander DA, Gallagher CJ.
Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins. 2024; 16(10):442.
https://doi.org/10.3390/toxins16100442
Chicago/Turabian Style
Dashtipour, Khashayar, Han S. Lee, Aaron Ellenbogen, Rashid Kazerooni, Todd M. Gross, David A. Hollander, and Conor J. Gallagher.
2024. "Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information" Toxins 16, no. 10: 442.
https://doi.org/10.3390/toxins16100442
APA Style
Dashtipour, K., Lee, H. S., Ellenbogen, A., Kazerooni, R., Gross, T. M., Hollander, D. A., & Gallagher, C. J.
(2024). Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins, 16(10), 442.
https://doi.org/10.3390/toxins16100442
